Ziphius, a leading biotechnology company developing self-amplifying RNA (saRNA) vaccines and therapeutics, is excited to announce the appointment of Jo Bury as non-executive Director and Chairman of the Board.
Jo Bury is co-founder and former managing director of VIB, the Flanders Institute for Biotechnology, a leading life science research institute, focused on breakthrough research in life sciences, translated a.o. in numerous spin off companies including Ablynx, Devgen, CropDesign, Multiplicom, Biotalis, Confo Therapeutics, Orionis Biosciences, Aphea.bio …. Before that Mr. Bury made a career in science policy after performing scientific research in the field of atherosclerosis during several years. He previously held the post of Operational Director of VLAB (Flanders’ Action Programme on Biotechnology) and was science advisor at federal and regional granting bodies (IWONL-IRSIA, IWT (now VLAIO).
Jo Bury has a Master’s degree in Pharmacy and is PhD in Pharmaceutical Sciences (University of Gent). He obtained an MBA degree at the Vlerick School for Management in Gent.
Jo Bury, upon his appointment, commented: “It is a privilege to be a part of Ziphius’ journey to becoming a clinical-stage biopharmaceutical company. Their groundbreaking saRNA and LNP technology and commitment to innovation are truly inspiring. I look forward to collaborating with the passionate team to push the boundaries in saRNA development.” Chris Cardon, CEO of Ziphius continued: "It’s an honour to welcome Jo as Chairman of our Board. I look forward to working together, leveraging his leadership in science and acute understanding of start-up innovation as we continue to drive forward our mission to reduce the global impact of infectious diseases on global health care by creating a new generation of transformative vaccines."
About Ziphius
Ziphius is a biotechnology company developing best-in-class vaccines and therapeutics based on its proprietary saRNA and carrier technology (LNP) platform to allow for a higher and prolonged protein/antigen expression at lower doses compared to conventional mRNA with reduced toxicity. This platform has the potential for a ‘plug and play’ approach offering the possibility of fast development/scale-up and production. These attributes make it well suited as platform to improve pandemic preparedness. Based in Ghent (Belgium) and New York (US) the companies present pipeline showcases strategic developments in infectious diseases, protein replacement therapies and a cutting-edge oncology program.
For more information, visit www.ziphius.org, and follow us on LinkedIn.